Physician profile
Mark S Reyn
NPI 1225064546
$4,832.95
in general payments reported to CMS, 2019-2025
22 companies · $29.74 in 2025
The $29.74 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,527 · 2020: $763 · 2021: $1,379 · 2022: $586 · 2023: $338 · 2024: $210 · 2025: $29.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,368.87 | 2019-2025 | |
| Allergan, INC. | $709.27 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $523.29 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $471.57 | 2019-2024 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $367.56 | 2020-2024 | Linzess |
| Lilly USA, LLC | $277.36 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $210.31 | 2019-2021 | |
| Amgen INC. | $207.68 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.55 | 2019-2022 | |
| Horizon Therapeutics Plc | $107.29 | 2021-2022 | |
| Pfizer INC. | $106.99 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.70 | 2019-2021 | |
| Radius Health, INC. | $62.80 | 2019 | |
| Merck Sharp & Dohme LLC | $44.93 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $43.93 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $28.59 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $14.93 | 2021 | |
| Eisai INC. | $14.18 | 2021 | |
| Aimmune Therapeutics, INC. | $13.16 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $12.90 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.00 | 2022 | |
| Novo Nordisk INC | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Reyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.